JP6549107B2 - がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ - Google Patents

がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ Download PDF

Info

Publication number
JP6549107B2
JP6549107B2 JP2016520399A JP2016520399A JP6549107B2 JP 6549107 B2 JP6549107 B2 JP 6549107B2 JP 2016520399 A JP2016520399 A JP 2016520399A JP 2016520399 A JP2016520399 A JP 2016520399A JP 6549107 B2 JP6549107 B2 JP 6549107B2
Authority
JP
Japan
Prior art keywords
chloro
fluoro
phenyl
capecitabine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016520399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521760A (ja
JP2016521760A5 (enExample
Inventor
ブライアン ヒギンス，
ブライアン ヒギンス，
グウェン ニコルズ，
グウェン ニコルズ，
キャスリン イー． パックマン，
キャスリン イー． パックマン，
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2016521760A publication Critical patent/JP2016521760A/ja
Publication of JP2016521760A5 publication Critical patent/JP2016521760A5/ja
Application granted granted Critical
Publication of JP6549107B2 publication Critical patent/JP6549107B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
JP2016520399A 2013-06-19 2014-06-16 がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ Expired - Fee Related JP6549107B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836899P 2013-06-19 2013-06-19
US61/836,899 2013-06-19
PCT/EP2014/062496 WO2014202497A1 (en) 2013-06-19 2014-06-16 Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy

Publications (3)

Publication Number Publication Date
JP2016521760A JP2016521760A (ja) 2016-07-25
JP2016521760A5 JP2016521760A5 (enExample) 2017-03-09
JP6549107B2 true JP6549107B2 (ja) 2019-07-24

Family

ID=50976625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016520399A Expired - Fee Related JP6549107B2 (ja) 2013-06-19 2014-06-16 がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ

Country Status (12)

Country Link
US (1) US20160129034A1 (enExample)
EP (1) EP3010508B1 (enExample)
JP (1) JP6549107B2 (enExample)
KR (1) KR20160009677A (enExample)
CN (1) CN105263499B (enExample)
BR (1) BR112015030734A2 (enExample)
CA (1) CA2912743A1 (enExample)
ES (1) ES2747073T3 (enExample)
MX (1) MX2015017124A (enExample)
PL (1) PL3010508T3 (enExample)
RU (1) RU2015152175A (enExample)
WO (1) WO2014202497A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021033144A1 (en) * 2019-08-20 2021-02-25 Intas Pharmaceuticals Ltd. Oral suspension of capecitabine
CN113698435B (zh) * 2021-08-25 2023-09-29 中国人民解放军空军军医大学 一类含有p53-MDM2抑制剂的四价铂配合物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2644643C (en) * 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
SG10202102855RA (en) * 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
JP2016521760A (ja) 2016-07-25
KR20160009677A (ko) 2016-01-26
RU2015152175A3 (enExample) 2018-04-02
EP3010508A1 (en) 2016-04-27
MX2015017124A (es) 2016-03-07
EP3010508B1 (en) 2019-07-24
BR112015030734A2 (pt) 2017-07-25
RU2015152175A (ru) 2017-07-24
US20160129034A1 (en) 2016-05-12
WO2014202497A1 (en) 2014-12-24
CN105263499B (zh) 2019-11-15
CA2912743A1 (en) 2014-12-24
ES2747073T3 (es) 2020-03-10
HK1213475A1 (zh) 2016-07-08
CN105263499A (zh) 2016-01-20
PL3010508T3 (pl) 2019-12-31

Similar Documents

Publication Publication Date Title
ES2660263T5 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
JP2012515184A (ja) 大腸がんの治療方法
EP2817011B1 (en) Treatment of cancer
ES2848706T3 (es) Terapia de combinación contra el cáncer usando un compuesto azabicíclico
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
JP6549107B2 (ja) がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
JP6239745B2 (ja) がんの処置のための、ｒｏ５５０３７８１及びカペシタビンの組み合わせ
ES2896051T3 (es) Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
JP2003055208A (ja) 組み合わせ化学療法
HK1213475B (zh) 用於癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
JP2016521760A5 (enExample)
CN114712353A (zh) 烟酰胺及含有其的组合物的制药用途
TW200940061A (en) Combination comprising bosentan for treating ovarian cancer
HK1204956B (en) Treatment of cancer
JP2001261573A (ja) 腫瘍転移抑制剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161101

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170629

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170707

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190626

R150 Certificate of patent or registration of utility model

Ref document number: 6549107

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees